Sage Therapeutics (SAGE) News Today → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Free sage Stock Alerts $13.04 +0.46 (+3.66%) (As of 04/18/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineQ1 2024 Earnings Estimate for Sage Therapeutics, Inc. (NASDAQ:SAGE) Issued By Wedbushmarketbeat.com - April 19 at 8:17 AMSage Therapeutics (NASDAQ:SAGE) Stock Rating Reaffirmed by HC Wainwrightamericanbankingnews.com - April 19 at 2:31 AMSage Therapeutics (NASDAQ:SAGE) Rating Reiterated by Wedbushamericanbankingnews.com - April 19 at 2:31 AMSage Therapeutics (NASDAQ:SAGE) Cut to Underperform at Bank of Americaamericanbankingnews.com - April 19 at 1:44 AMSage Therapeutics (NASDAQ:SAGE) Trading Up 6.2%marketbeat.com - April 18 at 4:33 PMScotiabank Lowers Sage Therapeutics (NASDAQ:SAGE) Price Target to $19.00marketbeat.com - April 18 at 10:28 AMB of A Securities Downgrades Sage Therapeutics (SAGE)msn.com - April 18 at 10:27 AMIn-Depth Examination Of 9 Analyst Recommendations For Sage Therapeuticsmarkets.businessinsider.com - April 18 at 10:27 AMSage Therapeutics (NASDAQ:SAGE) Given Hold Rating at Needham & Company LLCmarketbeat.com - April 18 at 8:23 AMSage Therapeutics (SAGE) Scheduled to Post Earnings on Thursdayamericanbankingnews.com - April 18 at 2:48 AMSage Therapeutics stock plunges 20 percent after Parkinson’s drug fails studymsn.com - April 17 at 6:40 PMWedbush Reiterates Neutral Rating for Sage Therapeutics (NASDAQ:SAGE)marketbeat.com - April 17 at 3:51 PMNeurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Databenzinga.com - April 17 at 1:38 PMBofA downgrades Sage to underperform, cites failed Parkinson's studymsn.com - April 17 at 1:38 PMNasdaq Down Over 1%; Sage Therapeutics Shares Plungemarkets.businessinsider.com - April 17 at 1:38 PMSage Stock Collapses To Record Low After Parkinson's Drug Misses Its Markfinance.yahoo.com - April 17 at 1:38 PMSage Therapeutics (NASDAQ:SAGE) Shares Gap Down to $15.63marketbeat.com - April 17 at 11:37 AMSage Therapeutics Hammered After Parkinson's Drug Misses The Markinvestors.com - April 17 at 8:46 AMSage Therapeutics Stops Further Development of Dalzanemdor in Parkinson's Diseasemarketwatch.com - April 17 at 8:38 AMSage Therapeutics Shares Sink Premarket After Setback in Development of Dalzanemdormarketwatch.com - April 17 at 8:38 AMSage Therapeutics' Dalzanemdor Phase 2 Study Fails To Meet Primary Endpointmarkets.businessinsider.com - April 17 at 8:38 AMSage drops after mid-stage setback for Parkinson’s disease candidatemsn.com - April 17 at 8:38 AMSage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage studyreuters.com - April 17 at 8:38 AMSage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Diseasefinance.yahoo.com - April 17 at 8:38 AMSage Therapeutics (NASDAQ:SAGE) Hits New 1-Year Low at $15.06marketbeat.com - April 16 at 2:58 PMLeerink Partnrs Research Analysts Boost Earnings Estimates for Sage Therapeutics, Inc. (NASDAQ:SAGE)americanbankingnews.com - April 13 at 1:28 AMQ1 2024 EPS Estimates for Sage Therapeutics, Inc. (NASDAQ:SAGE) Raised by Analystmarketbeat.com - April 12 at 6:08 AMSage Therapeutics (NASDAQ:SAGE) Hits New 1-Year Low at $15.88americanbankingnews.com - April 12 at 4:06 AMSage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Recommendation of "Hold" by Brokeragesamericanbankingnews.com - April 12 at 2:48 AMSage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024businesswire.com - April 11 at 6:30 AMVanguard Group Inc. Has $107.18 Million Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)marketbeat.com - April 5 at 4:06 AMSage Therapeutics (NASDAQ:SAGE) Hits New 12-Month Low at $16.48marketbeat.com - April 4 at 6:52 PMZelda: Tears of the Kingdom T-shirts are coming to Uniqlo in late Aprilmsn.com - April 3 at 9:25 PMWe're Keeping An Eye On Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Ratefinance.yahoo.com - March 28 at 11:11 AMDemystifying Sage Therapeutics: Insights From 5 Analyst Reviewsmarkets.businessinsider.com - March 26 at 2:07 PMSage Therapeutics (NASDAQ:SAGE) Shares Gap Up Following Analyst Upgrademarketbeat.com - March 26 at 12:42 PMSage Therapeutics (NASDAQ:SAGE) Price Target Increased to $29.00 by Analysts at JPMorgan Chase & Co.marketbeat.com - March 26 at 8:47 AMSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Teachers Retirement System of The State of Kentuckymarketbeat.com - March 22 at 4:35 AMThis company is treating postpartum depression in 2 weeks with a daily pillmsn.com - March 20 at 7:20 PMSage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Recommendation of "Hold" by Analystsmarketbeat.com - March 18 at 2:56 AMSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Bought by Citigroup Inc.marketbeat.com - March 17 at 5:10 AMHudson Bay Capital Management LP Raises Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)marketbeat.com - March 15 at 6:57 AMJacobs Levy Equity Management Inc. Acquires Shares of 391,231 Sage Therapeutics, Inc. (NASDAQ:SAGE)marketbeat.com - March 13 at 6:56 AMSage Therapeutics Inc.barrons.com - March 11 at 4:25 AMSchonfeld Strategic Advisors LLC Raises Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)marketbeat.com - March 7 at 6:40 AMRTW Investments LP Purchases New Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)marketbeat.com - March 6 at 11:00 AMSage Therapeutics, Inc. (NASDAQ:SAGE) Holdings Lifted by Palo Alto Investors LPmarketbeat.com - March 1 at 10:27 AMPeeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insightsmarkets.businessinsider.com - February 28 at 5:41 PMAlgert Global LLC Makes New $1.17 Million Investment in Sage Therapeutics, Inc. (NASDAQ:SAGE)marketbeat.com - February 28 at 6:37 AMSage Therapeutics to Present at Upcoming March Investor Conferencesbusinesswire.com - February 28 at 6:30 AM Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New crypto project uncovers 2,050% in 65 days (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024. Just click here to sign up and be among the first to get it. SAGE Media Mentions By Week SAGE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAGE News Sentiment▼-0.180.53▲Average Medical News Sentiment SAGE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAGE Articles This Week▼365▲SAGE Articles Average Week Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: 89bio News Today OPKO Health News Today ABIVAX Société Anonyme News Today Innoviva News Today ARS Pharmaceuticals News Today Pliant Therapeutics News Today Tyra Biosciences News Today Cassava Sciences News Today Centessa Pharmaceuticals News Today Zentalis Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAGE) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe “Perfect Storm” for GoldGold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.